Roche Venture Fund reinvests as Horizon Discovery closes series C funding round at $29.1m.
UK-based personal medicine company Horizon Discovery has raised a further £6.9m ($10.5m)in its series C funding round, led by Dr. Jonathan Milner, CEO, Abcam Plc, with existing investors DFJ Esprit, MVM Life Science, Roche Venture Fund (corporate venturing unit of Switzerland-based pharmaceuticals company Roche), David Evans, Peter Collins, and Providence Investment Company Limited also participating. New investors include Wren Capital, Calculus Capital, the University of Cambridge Enterprise Fund and members of Horizon’s senior management team.
The series C round is…
